Podcasts about tumors

In this episode of Healthy Mind, Healthy Life, host Avik welcomes Riza August, who shares her inspiring journey of resilience and self-discovery following a brain tumor diagnosis. Riza discusses her decision to reclaim her life through an 1845-mile bike journey, the emotional and spiritual growth she experienced, and the importance of sharing her story to help others heal. The conversation emphasizes the power of perspective, the significance of taking small steps towards recovery, and the ongoing journey of personal transformation. Takeaways Riza made a conscious decision to live after her diagnosis. The bike journey was a spiritual testament to perseverance. Healing can be facilitated through sharing one's story. Vulnerability is a powerful form of medicine for the soul. Asking 'What can I do?' can shift one's perspective. Even small steps can lead to extraordinary outcomes. Riza's journey opened her up to new experiences and opportunities. Embracing change is essential for personal growth. Healing and growth are lifelong practices. We are all worthy of healing and transformation.   Chapters 00:00 Introduction to Riza's Journey 02:02 The Decision to Live 03:44 Reflecting on Life's Choices 05:23 The Spiritual Journey of Biking 06:49 Healing Through Sharing 09:51 Overcoming Limitations 12:19 Embracing Change and Growth 13:46 Continuing the Journey of Transformation   Watch Video: https://youtu.be/XHyzG1sC-ns    Reach Risa: Facebook: https://www.facebook.com/risa.august.unleashed/ Instagram: https://www.instagram.com/risaunleashed/ LinkedIn: www.linkedin.com/in/risa-august-9b130524a      Disclaimer: This video is for educational and informational purposes only. The views expressed are the personal opinions of the guest and do not reflect the views of the host or Healthy Mind By Avik™️. We do not intend to harm, defame, or discredit any person, organization, brand, product, country, or profession mentioned. All third-party media used remain the property of their respective owners and are used under fair use for informational purposes. By watching, you acknowledge and accept this disclaimer.   -----   Healthy Mind By Avik™️ is a global platform redefining mental health as a necessity, not a luxury. Born during the pandemic, it's become a sanctuary for healing, growth, and mindful living. Hosted by Avik Chakraborty storyteller, survivor, wellness advocate this channel shares powerful podcasts and soul-nurturing conversations on:   • Mental Health & Emotional Well-being • Mindfulness & Spiritual Growth • Holistic Healing & Conscious Living • Trauma Recovery & Self-Empowerment   With over 4,500+ episodes and 197.4K+ global listeners, join us as we unite voices, break stigma, and build a world where every story matters.  

Cats deserve cancer breakthroughs too! Dr. Sue Ettinger, DVM, DACVIM (Oncology), shares what's on the horizon for feline cancer testing in the next episode of the Purr Podcast. Known on social media as Dr. Sue Cancer Vet, she is an international speaker, author, & vlogger. She is a board-certified specialist in medical oncology. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003.Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.

BUFFALO, NY – October 14, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on October 13, 2025, titled “Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields.” The study, led by Hugo Jimenez from Wayne State University School of Medicine, Karmanos Cancer Institute, introduces a novel treatment approach for glioblastoma, an aggressive and often treatment-resistant brain cancer. The findings open a new potential path for patients who currently have limited therapeutic options. The approach uses a device developed by TheraBionic that delivers extremely low levels of radiofrequency electromagnetic fields, tuned to frequencies associated with glioblastoma. In laboratory experiments, this therapy significantly slowed the growth of multiple glioblastoma cell lines. It was especially effective against tumor stem cells, which are known to resist standard treatments and drive cancer reappearance. Researchers also found that the treatment's effects depend on a calcium channel in tumor cells known as Cav3.2 (CACNA1H). When this channel was blocked, the therapy lost its effectiveness, highlighting the channel's essential role in how tumor cells respond to the signal. The therapy also disrupted the process of cell division by interfering with the mitotic spindle, a structure critical for cell replication. This disruption was associated with changes in the expression of genes that regulate cell division, particularly those involved in the “Mitotic Roles of Polo-Like Kinase” pathway. These effects were specific to tumor-targeted frequencies, as non-matching signals had no measurable impact. The study also includes data from two patients with difficult-to-treat brain tumors who received the therapy through compassionate use. One patient with recurrent glioblastoma showed signs of clinical and radiographic improvement after one month of treatment. Another patient with oligodendroglioma tolerated the therapy well and had stable disease during follow-up imaging. Neither patient experienced serious side effects, further supporting the safety of the therapy. “There was evidence of clinical and radiological benefit in a 38-year-old patient with recurrent GB and evidence of safety and feasibility in a 47-year-old patient with oligodendroglioma.” This is the first study to demonstrate that tumor-specific radiofrequency therapy can suppress both tumor growth and cancer stem cells in glioblastoma. Similar results had previously been observed in liver and breast cancers. These findings contribute to the growing body of evidence supporting a new class of systemic, non-toxic cancer therapies. Further clinical trials will be crucial to confirm these results and fully assess the potential of this approach for treating brain cancer. DOI - https://doi.org/10.18632/oncotarget.28770 Correspondence to - Hugo Jimenez - hugo.jimenez@wayne.edu Abstract video - https://www.youtube.com/watch?v=uxYnWcNKYfg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28770 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oncology, amplitude-modulated radiofrequency electromagnetic fields, glioblastoma, TheraBionic, CACNA1H, Cav3.2 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.---This podcast is supported by:Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care.---TIMESTAMPS0:00 - Introduction02:20 - Case 1 (Incidental Renal Mass)16:52 - Case 2 (Bilateral Renal Masses)37:22 - Case 3 (Locally Advanced Renal Mass)56:34 - Case 4 (Symptomatic, Metastatic Disease)01:14:00 - Final Takeaways

Krebs bei jungen Menschen; Quarks Radio; KI kann Gefühle; Kommentar: Nobelpreis - ein veraltetes Ritual?; Nobelpreis Physik; Wie kann guter Umgang mit TikTok aussehen?; Wie sinnvoll sind Trigger-Warnungen?; Warum Frauen länger leben als Männer; Risiken und Nebenwirkungen von Psychotherapie; Moderation: Marlis Schaum. Von WDR 5.

In this episode with Meagan Lindquist, you’ll discover the world of AHCC, a cultured mushroom extract with a remarkable range of health benefits. We explore its origins, patented culturing process in Japan, and what makes AHCC uniquely bioavailable compared to other mushroom supplements. Meagan shares her health journey, her experiences supporting patients, and her passion for spreading awareness about AHCC’s research-backed potential—from cancer and HPV to Lyme disease and overall immune function. The conversation highlights AHCC’s role as an immunomodulator, antioxidant, and anti-inflammatory compound, reviewing studies that demonstrate its benefits for general immune support and as complementary therapy for serious conditions, such as cancer and chronic infections. Practical topics include supplement quality, dosing, and how to find credible sources. By the end, you’ll have insights and actionable information to evaluate AHCC as part of a thoughtful, science-driven approach to immune optimization and integrative health. Meagan (Mimi) Lindquist (@mimi_themedicin) is the co-founder of The Medicin, alongside her husband Chase. Together, they provide high-quality mushroom products to the world. With her background as a clinical dental hygienist, nutrition guide, and AHCC educator, she has been helping others prevent disease for over 12 years. Now, Mimi is dedicated to sharing the benefits of Immune Intel AHCC, a mushroom product unlike any other, to as many people as possible. She hosts monthly live calls with Dr. Nathan Riley for women trying to clear HPV naturally using AHCC. In her words, it is her "life's passion to spread the word about how powerful it is." Full show notes: bengreenfieldlife.com/ahccpodcast Episode Sponsors: Organifi Shilajit Gummies: Harness the ancient power of pure Himalayan shilajit anytime you want with these convenient and tasty gummies. Get them now for 20% off at organifi.com/Ben. BlockBlueLight: BlockBlueLight BioLights are the only lights extensively tested and recommended by building biologist Brian Hoyer as truly flicker-free, ultra-low EMF, and circadian-friendly, with three modes (day, evening, night) that support natural rhythms and optimize sleep quality. Get 10% off your first order at blockbluelight.com/Ben (discount autoapplied at checkout). Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. LVLUP Health: I trust and recommend LVLUP Health for your peptide needs as they third-party test every single batch of their peptides to ensure you’re getting exactly what you pay for and the results you’re after! Head over to bengreenfieldlife.com/lvluphealth and use code BEN15 for a special discount on their game-changing range of products. BiOptimizers Magnesium Breakthrough: The 7 essential forms of magnesium included in this full spectrum serving help you relax, unwind, and turn off your active brain after a long and stressful day so you can rest peacefully and wake up feeling refreshed, vibrant, and alert. Go to bioptimizers.com/ben and use code ben15 for 15% off any order.See omnystudio.com/listener for privacy information.

10-03-25 - New Update On Tumor Listener Gary His Wife Who Flew To See Him In Hospital - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

10-03-25 - New Update On Tumor Listener Gary His Wife Who Flew To See Him In Hospital - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Is microwave ablation only for simple liver tumors, or can it be a versatile ‘Swiss Army knife' for a wide range of complex cases? In this episode, Dr. Driss Raissi of the University of Kentucky returns to BackTable to join host Dr. Chris Beck for a deep dive into advanced and unconventional microwave ablation techniques. They cover strategies for tackling a wide range of cases, from desmoid tumors to enterocutaneous fistulas.---This podcast is supported by:Medtronic Emprinthttps://www.medtronic.com/emprint---SYNPOSISDr. Raissi shares his ‘pre-burn' technique that desiccates tissue and reduces complications like capsular burst and bleeding. He elaborates on his method for tackling large liver tumors with a single probe through overlapping ablations, needle placement techniques and his ‘lung seal technique' to prevent pneumothorax. Dr. Raissi also shares how his previous experience in the ICU promotes close communication with anesthesiologists and how he ups his ablation game through collaboration, optimizing conditions for safe and effective ablation.The episode explores a series of unique, real-world applications beyond the usual scope of IRs. Dr. Raissi walks us through his novel approach to challenging cases, including cauterization of enterocutaneous fistulas, endometriomas and desmoid tumors. He also compares using microwave or cryoablation for renal cell carcinoma, explaining thought processes based on lesion location and the need for speed and simplicity. The discussion provides an overview of ablation physics and careful techniques that expand treatment possibilities for IR patients.---TIMESTAMPS00:00 - Introduction 04:08 - Advanced Techniques for Liver Tumor Ablation06:06 - Pre-Burning Ablation and Ablating a Range of Lesions16:38 - Lung Ablation22:00 - Partnering with Anesthesia28:53 - Managing Postoperative Pain and Nerve Injuries29:42 - Treating Enterocutaneous Fistulas, Endometriomas & Desmoid Tumors38:49 - Adrenal Gland Ablation: A Case Study44:50 - Microwave vs. Cryoablation for Renal Cell Carcinoma49:06 - Preventing Pneumothorax in Lung Ablation

Guest: Danielle O'Laughlin, PA-C, MS Hosts: Danielle O'Laughlin, PA-C, MS and Jenna Wygant, APRN, CNP, DNP In this episode, Danielle O'Laughlin discusses benign breast tumor conditions and other non-cancerous growths. Listeners will gain insight into the clinical presentation, diagnostic evaluation, and management strategies for these common breast findings. Learning Objectives: Review the types of benign breast tumors and their clinical features. Differentiate between symptoms, diagnostic approaches, and treatment options for various benign breast conditions. Learn more about this series: Mayo Clinic Talks: Obstetric and Gynecologic Health | Mayo Clinic School of Continuous Professional Development Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

In this groundbreaking episode, we dive deep into MOJO Health's "Data Iceberg" concept that's revolutionizing cancer care. Many people make life-changing medical decisions using only 2 types of data - biopsy results and imaging scans. If you go to the most advanced cancer centers, you likely use 6, but there are 7 additional categories of health data hiding beneath the surface that will transform your healing strategy.What You'll Discover:- Why most healthcare operates on "tip of the iceberg" data- The 13 hidden data categories that predict treatment success- How molecular DNA profiling creates personalized treatment roadmaps- The power of circulating tumor DNA (liquid biopsies) for real-time monitoringPerfect for: Cancer patients, survivors, caregivers, healthcare advocates, and anyone who wants to transform from reactive to proactive healthcare.Remember: Data G's don't just hope their treatment is working. They know.Resources Mentioned:For our downloadable Guide to Be a Data G, please go to mojohealth.org/datagguideTo set up an appointment with Oscar Sierra, please reach out to https://www.sierracollaborativemed.com/To see National Cancer Institute's page the blood biomarkers: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-listAnd here for information on different types of data to request: https://www.mojohealth.org/be-a-data-g-1Other Podcasts to watch:#4 A Data G's Guide to Beating Cancer w/ Julie Stevens and Oscar Sierra, L.Ac.#6 BRCA2 Data Dilemma: Lessons in Gene Expression#8 How Genomic Testing Can Transform Your Cancer JourneyWhat tests do you need your doctor to order? Biopsy, Imaging, Circulating Tumor DNA, and Molecular DNA of the Tumor.Basically everything else you can order on your own through Direct Patient Labs: https://www.mojohealth.org/direct-labs-mojo-panelsConnect with Julie Stevens and the MOJO Movement: Instagram: https://instagram.com/mojohealthorg TikTok: https://tiktok.com/@julie.stevens97YouTube: https://www.youtube.com/@mojohealth Facebook: https://facebook.com/mojohealthorg Website: https://www.mojohealth.org/DISCLAIMER: The views, thoughts, and opinions expressed on this podcast are the speaker's own and do not represent the views, thoughts, and opinions of MOJO Health Cooperative LLC, a Georgia Limited Liability Company, its respective officers, directors, employees, agents, or representatives. This podcast is presented by MOJO Health Cooperative, and cannot be copied or rebroadcast without consent. The material and information presented here is for general information purposes only, and not intended to supplant the expert advice and/or consultation of a medical doctor and/or a licensed physician, and/or an attorney. In short, this podcast is not intended to replace professional medical advice, nor legal advice. The "MOJO Health" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service. Again, none of the content of this podcast should be considered legal advice, nor medical advice. As always, consult a lawyer and/or a licensed physician in lieu of relying upon the advice of any of the participants of this podcast. The host(s) of this podcast are not licensed lawyers, physicians, doctors of osteopath, nor medical doctors in any jurisdiction anywhere. The host(s) of this podcast do not practice medicine and do NOT profess to be able to do any of the following: (1) diagnose, heal, treat, prevent, prescribe for, or removing any physical, mental, or emotional ailment or supposed ailment of an individual; (2) engage in the end of human pregnancy; (3) treat human ailments; nor (4) perform acupuncture. MOJO Health Cooperative LLC is not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.

In this episode we catch up with Zack Round. Zack is known as the Tumor Warrior and does a lot for others who suffer from brain tumors like Zack had. We get to catch up and talk about his re-branding in this episode. Support for the Segment Podcast are brought to you by:THE SEGMENT / DISCOUNT CODES / SUPPORTERSYT Industrieshttps://us.yt-industries.com/Etnies MTB Shoes: Promocode TheSegment30https://etnies.com/collections/bike-mtb Versus Tires: www.versustires.comTASCO MTB Apparel 15% offhttps://tasco-mtb-2.kckb.st/3bb12b05Promo Code: SEGMENT24 Spy Optic: https://www.spyoptic.com/Promo code SEGMENT20  20% off your purchaseKapu CoffeePurchase "The Sender" here: https://kapucoffee.com/pages/segment25% of the proceeds help the charity "Making Spirits Bright" which helps get kids outside and on bikes.https://msbfoundation.org/Kali Protectiveshttps://kaliprotectives.com/collections/full-face/products/dh-invader?variant=41188142481502Promo Code Segment25Mother Earth Brew Company: https://www.motherearthbrewco.com/PelliBikeCare: https://www.pellibikecare.com/Strong Coffee: 15% off https://strongcoffeecompany.com/?ref=Segment30Or use promo code SEGMENT15 at checkout. To become a Podcaster for Free try this link:   https://streamyard.com/pal/c/4674191405613056PHAT Lids: https://www.phatlids.com/Use promo code SEGMENT to get 10% off at checkout. SALTSTICK https://aletenutrition.com/pages/saltstick Use promo code SEGMENT20 to get 20% off

The only way to follow up last week's milestone is with the rarest of the rare medical cases. Fun. — Support and sponsor this show! Venmo Tip Jar: @wellthatsinteresting Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wellthatsinterestingpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bluesky: @wtipod Threads: @wellthatsinterestingpod Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wti_pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Listen on YouTube!! Oh, BTW. You're interesting. Email YOUR facts, stories, experiences... Nothing is too big or too small. I'll read it on the show: wellthatsinterestingpod@gmail.com WTI is a part of the Airwave Media podcast network! Visit AirwaveMedia.com to listen and subscribe to other incredible shows. Want to advertise your glorious product on WTI? Email me: wellthatsinterestingpod@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textDr Kate Lund is a psychologist, TEDx speaker, and podcast host of The Optimized Mind, and she spends her days helping people turn those "what now?" Moments into genuine resilience.. Her work centers on translating over 20 years of research into simple, science-backed habits that real humans can use during in their hardest of times, whether they're navigating parenthood, setbacks, or that feeling of life falling apart.Dr Kate talks about her early childhood with hydrocephalus, (she explains what that is!!) and subsequent tumor diagnosis, and how that set her apart as different than her peers and at the same time fostered a sense of resilience and possibility beyond the challenges. As a best selling author, she has seen firsthand how messy, imperfect resilience can change someone's story. Her book, ‘Step Away: The Keys to Resilient Parenting', is out in October 2025. Book: https://a.co/d/4CaffaCSite: Www.katelundspeaks.com TedX: https://www.youtube.com/watch?v=-p6YcTsWySU&t=14sThe Dom Sub Living BDSM and Kink PodcastCurious about Dominance & submission? Real stories, real fun, really kinky.Listen on: Apple Podcasts SpotifySupport the show

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast audience. Joining him is Dr. Ash Alizadeh, the Moghadam Family Professor of Medicine, Oncology, and Hematology at Stanford University and leader of the Cancer Genomics Program at Stanford Cancer Institute. Dr. Alizadeh has been instrumental in advancing our understanding of lymphomagenesis and lymphoma genetics over the past two decades, pioneering multiple ctDNA techniques that are revolutionizing cancer care. Together, they discuss the transformative potential of ctDNA technology in B-cell lymphomas, particularly DLBCL, covering everything from the technical evolution of biomarker detection to groundbreaking clinical data that may reshape how we monitor and treat these aggressive cancers. Key Discussion Topics1. Genetic Heterogeneity in B-Cell LymphomasComplex genetic landscape of DLBCLImplications for treatment strategiesNeed for personalized approaches 2. Clinical Need for ctDNA in LymphomaWhy ctDNA is needed in aggressive lymphomas:Curative vs. non-curative treatment settingsLimitations of current PET imagingAdditional prognostic information beyond imagingRisk stratification capabilitiesPotential to avoid overtreatmentTherapy adaptation opportunities 3. Challenges in Lymphoma MRD AssessmentWhy lymphoma MRD is more complex than other hematologic malignancies:Differences from acute leukemias, CLL, and myelomaTechnical challenges specific to lymphoid tumorsLower circulating tumor burden compared to liquid tumors 4. ClonoSEQ TechnologyMechanism: Immunoglobulin sequencing approachAdvantages: Established platform with regulatory approvalDisadvantages: Limited sensitivity in peripheral blood, requires adequate tumor sample 5. CAPP-Seq TechnologyFull Name: Cancer Personalized Profiling by Deep SequencingInnovation: Developed ~10 years ago by Dr. Alizadeh's groupMechanism: Targeted sequencing of cancer-specific mutationsAdvantages: High sensitivity, personalized approach 6. PhasED-Seq TechnologyEvolution: Next-generation advancement of CAPP-SeqKey Improvements: Enhanced sensitivity and specificityTechnical Advances: Phased variant detection Clinical Data Highlights1. Remission Assessment by ctDNA in LBCL on 5 prospective studies of frontline anthracycline-based chemo-immunotherapy: https://pubmed.ncbi.nlm.nih.gov/40802906/2. Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from HOVON-902 clinical trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.70003. Korean data on prognostic utility of ctDNA: https://ashpublications.org/blood/article/142/Supplement%201/69/501573 

BUFFALO, NY - September 24, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on September 22, 2025, titled “Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.” In this study, led by first author Jacob Haagsma and corresponding author Trevor G. Shepherd from the Verspeeten Family Cancer Centre and Western University, Canada, researchers investigated how the loss of Trp53 – a critical tumor suppressor gene – affects immune responses in ovarian cancer. The team found that deleting Trp53 led to more aggressive tumor growth and a weaker immune response. These findings help explain why some ovarian tumors may be resistant to immunotherapy and point to new ways to improve treatment. High-grade serous ovarian carcinoma (HGSC) is a deadly cancer that is often diagnosed at a late stage. Immunotherapy, which enhances the body's immune system to fight cancer, has shown limited effectiveness in treating this type of cancer. To better understand why, the researchers developed a mouse model that closely mimics human HGSC. They injected ovarian epithelial cells, with and without Trp53, into the fallopian tubes, the origin site of most ovarian cancers. “In this study, we developed a syngeneic model reflecting both the site of origin and the genotype of early HGSC disease by deleting Trp53 in mouse oviductal epithelial (OVE) cells.” Mice injected with cells lacking Trp53 developed faster-growing and more invasive tumors, reflecting how the disease typically progresses in humans. These tumors also had fewer active T cells, which are immune cells responsible for attacking cancer. Moreover, the T cells that were present appeared less capable of responding to the tumor, creating an immune environment that allowed cancer to grow uncontrolled. Further analysis revealed that tumor cells without Trp53 had reduced activity in genes related to inflammation. These changes were associated with lower levels of key proteins that normally help immune cells detect and attack tumor cells. When the researchers collected tumor cells from the abdominal fluid of the mice—a condition that simulates advanced-stage disease—they observed even lower immune signaling than before. This suggests that as the tumor spreads, it becomes better at evading the immune system. This study highlights how early genetic mutations can shape the interaction between tumors and the immune system. In particular, the loss of Trp53 appears to trigger a chain of events that weakens immune surveillance and accelerates tumor progression. These findings emphasize the need to consider both genetic mutations and the tumor environment when designing immunotherapies for ovarian cancer. Understanding how genes like Trp53 influence immune behavior may lead to more effective treatments and help identify which patients are most likely to benefit from immunotherapy. DOI - https://doi.org/10.18632/oncotarget.28768 Correspondence to - Trevor G. Shepherd - tshephe6@uwo.ca Abstract video - https://www.youtube.com/watch?v=WFQw0psuC3M Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28768 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Colorectal cancer is one of the most common—and deadliest—cancers worldwide. Once it spreads and reaches the metastatic stage, treatment becomes far more difficult. Tumors can also behave very differently from one patient to another, especially after multiple rounds of therapy. Precision oncology is helping to overcome these challenges by enabling clinicians to analyze each tumor's unique genetic profile and tailor treatment accordingly. This approach was recently highlighted in a case study published in Volume 16 of Oncotarget. The report detailed how a 62-year-old man with advanced colorectal cancer received a highly personalized treatment plan, developed by an international panel of experts, after completing all standard treatment options. Full blog - https://www.oncotarget.org/2025/09/24/precision-oncology-in-metastatic-colorectal-cancer-a-real-world-case-study/ Paper DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Abstract video - https://www.youtube.com/watch?v=uWDtWNgpK7A Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28744 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board, colorectal carcinoma, cancer management To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

He let it go for 16 years!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Stupid News 9-23-2025 8am …Dumbest Lawsuit of the Year …He somehow got His Head Stuck inside a Traffic Light …It is a Tumor

Fr. Eric Nielsen joins Patrick to discuss Miracles: Padre Pio Who was Padre Pio and what miracles did he do? (14:03) Why do some people get miracles and others don’t? (17:19) Juliette - My father was in a bad accident. He is on a ventilator. Tried to remove it. Did not succeed. 84 years old. At what point is it too much. Miracle he survived. I feel like there have been some answered prayers. Is that a miracle in itself that he was able to communicate his wishes? (22:05) Break 1 (23:45) Helen - When my daughter was 3, my daughter had a brain tumor. She had tumor removed. Came back. Went through surgery again, I prayed and asked that she not suffer if she was going to be taken. Tumor disappeared and now she's 39 years old. She's my miracle baby. Does God allow bargaining? Dan - I worked as a hospice chaplain, and one of the greatest pieces of advice...sometimes we just need to get out of God's way and let God do what he needs to do. The miracle of bringing a soul to heaven is the ultimate miracle. (32:53) Brenda - My cousin heard mass by Padre Pio. Was part of my conversion to Catholicism. (37:10) Break 2 Barbara - Miracle when I was baptized. I was instantly delivered from smoking cigarettes. 45-year smoker. (41:59) Eileen - The priest who got me into my faith was leading a colorful life. Padre Pio told him he would become a priest one day. Love the story that he told him he would become a priest. Father shares an email about how can we pray when God doesn’t answer our prayer? (46:13) Brenda - Years after my mom passed, I was thinking about her and praying and walked to the living room and noticed a little star out of nowhere. I think it was a sign and miracle that she was there. Had this happen several other times. Miracle think it was the Lord saying 'I have them.'

We talk about how booing a DJ is in bad taste (and how some big acts need to know their fans suck), Coachella's yearly poster dedicated to font sizes, and the new Deftones, Water From Your Eyes and Kirby Records Hosted on Acast. See acast.com/privacy for more information.

Pathologen sind schrullige Typen, die im Tatort die Leichen aufschlitzen? Nicht vollkommen falsch, aber doch nur ein sehr kleiner Ausschnitt von dem, was Pathologen tatsächlich tun. Prof. Dr. Irina Berger ist Chefärztin der Pathologie am Klinikum Kassel. Sie versucht jeden Tag zu entschlüsseln, wie krankes Gewebe sich entwickelt, um mit diesem Wissen Tumore zu bekämpfen - und zwar passgenau für jeden Patienten.

There is a new treatment option available now that can precisely target prostate lesions with electrical pulses, while helping preserve sexual function and urinary control. Whether you or a loved one has prostate disease, or you are a urologist considering this technology for your practice, you will not want to miss today's discussion on this innovative new option. September is Prostate Cancer Awareness Month, so we have a special episode today to kick it off. We are excited to welcome the distinguished urologist, Dr. Spencer Krane, to the Prostate Health Podcast. Dr. Krane is the Chief of Urology at the US Department of Veterans Affairs in New Orleans, Louisiana. He specializes in personalized medicine for patients with urologic malignancies, aiming to use new biomarkers, genomic classifications, epigenetic signatures, and advanced imaging modalities, including MRI-guided prostate biopsies, to offer his patients individualized care that improves cancer outcomes while minimizing therapy side effects. Dr. Krane has published extensively in urologic journals, and his work was selected to provide guidelines for urologic care. He has 50 peer-reviewed articles in national and international journals and has presented his work internationally, from Chile and Rome to Taiwan, as well as across the United States. We are excited to welcome him today to share his experience with the innovative new NanoKnife system as a treatment option for men with prostate tumors.  It is exciting to see ongoing innovation in the technology we have available for men with prostate tumors. For the appropriate candidates, this minimally invasive option offers precise targeting of the lesion while helping preserve both sexual function and urinary control.  Pertinent disclosure for today's episode – Dr. Krane is a paid consultant for AngioDynamics, Inc., which manufactures and sells the NanoKnife System. The views, information, and opinions expressed in this podcast are solely those of Dr. Krane, and does not necessarily represent those of AngioDynamics, Inc., its affiliates, or subsidiaries.  Show Highlights: Dr. Krane reviews the concept of targeted focal therapy and explains what  the NanoKnife system is Who is an ideal candidate for irreversible electroporation with the NanoKnife system? The advantages and features of the NanoKnife system   Does prostate size or shape limit the candidacy for IRE with the NanoKnife system? Would prostate anatomies on the MRI or biopsy exclude a patient from NanoKnife therapy? Dr. Krane explains how long it takes to resolve the initial decrease in sexual ability after NanoKnife therapy.   Why many patients experience improved urinary function in the long term after having NanoKnife therapy Dr. Krane clarifies the time it takes to resolve the initial decrease in sexual ability after being treated with NanoKnife therapy.   Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd.  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on X and Instagram  Sign up for the Prostate Health Academy   You can access Dr. Pohlman's free mini-webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.  

Doctors often use euphemisms to dance around the 'C' word. But for oncologist Dr Ranjana Srivastava, how you talk to someone with cancer goes beyond "shadows, lumps and lesions". It's all about compassion and clarity, even when honesty is difficult.Ranjana Srivastava was a young doctor in regional Australia, accompanying her consultant on his late night rounds when she heard a patient say something that stopped Ranjana in her tracks.It was in that moment that she finally knew what her speciality was going to be: oncology. Ranjana now works in Melbourne as an oncologist and an author.She often writes about the need for clarity and compassion in doctor-patient conversations, to deliver good news, bad news and everything that falls between.Ranjana had her own experience of being at the receiving end of devastating news when she was pregnant with twins.Ranjana has carried the lesson she received from her own doctor forward, into her work as an oncologist, where bearing witness to the attitudes of her patients has changed the way she sees the world and has helped put her own life in perspective.Further informationRanjana's latest book, Every Word Matters, is published by Simon & Schuster.She has published seven books about cancer and end of life care, including A Better Death, Tell Me the Truth, Dying for a Chat, So It's Cancer: Now What, and After Cancer: A Guide to Living Well.Ranjana also writes a regular column for The Guardian.In 2017, Ranjana was awarded an Order of Australia medal for her work as an oncologist and in improving doctor-patient communication.This episode of Conversations was produced by Meggie Morris. Executive producer is Nicola Harrison.It explores cancer, oncology, the big C, cancerland, breast cancer, bowel cancer, how to survive cancer, incurable cancer, end of life care, palliative care, honest doctors, refusing treatment, chemotherapy, radiation, how to be honest with patients, doctor patient relationship, geriatric oncology, India, migration, motherhood, late term miscarriage, pregnancy, writing, books, origin story, journalism.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.---This podcast is supported by:Ferring Pharmaceuticals https://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.---TIMESTAMPS0:00 - Introduction1:48 - Active Surveillance in Low-Risk Prostate Cancer7:08 - Molecular Testing and Risk Stratification8:28 - Radiation Therapy Approaches20:16 - PSA Recurrence and PSMA PET Scans32:40 - The Role of ADT37:15 - PSMA PET Scans40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer46:54 - Treatment Intensification vs. De-Intensification Trials55:59 - Castration-Resistant Prostate Cancer

In episode 93 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Dr. Nur Damayanti, cancer researcher at IU School of Medicine. Tune in as Dr. Damayanti shares the personal cancer diagnosis that changed the trajectory of her career and the Heroes Foundation funding that is supporting her project to study new treatment methods for children with rare brain cancers. Learn more about recent Heroes Foundation gifts: https://www.heroesfoundation.org/the-heroes-foundation-has-awarded-nine-exciting-indiana-cancer-projects-with-223500-in-funding/

Love the episode? Send us a text!In this special episode of Breast Cancer Conversations, host Laura Carfang speaks with Dr. Troso  about the evolving role of DNA testing in breast cancer care. Together, they break down the three main types of testing:Hereditary genetic testing: Identifying inherited mutations such as BRCA1, BRCA2, and PALB2 (among others) that increase cancer risk and influence prevention and treatment decisions.Somatic (tumor) testing: Analyzing mutations within the tumor itself—such as PIK3CA or ESR1 mutations—to guide targeted therapies and manage resistance in advanced disease.Circulating tumor DNA (ctDNA) testing: Also known as a liquid biopsy, this emerging tool uses blood tests to detect cancer DNA fragments. It holds promise for monitoring recurrence, guiding treatment earlier, and advancing clinical trials.Tune into this Special! 

S3E9: Case based work up and management of Wilms Tumor feat Dr. Megan Orr

Dr. Morse Q&A - Infertility - Burns - Uterine Cancer - Thyroid Tumor #792 00:00:00 - Intro 00:03:58 - Infertility 00:26:40 - Growths - Dying Tooth - Brittle Nails - Breastfeeding 00:58:26 - Burns 01:07:52 - Uterine Cancer - Non-Stop Period/Bleeding - Unbearable Cramps - Pain - Weight Loss 01:26:36 - Thyroid Tumor - Balding - Tinnitus - Rashes - High Bilirubin  - High Testosterone 00:03:58 - Infertility The supposed cause was hydrosalpinx (fluid-filled fallopian tubes).  00:26:40 - Growths - Dying Tooth - Brittle Nails -Breastfeeding I gave birth eleven months ago and feel I haven't fully healed since.  00:58:26 - Burns Can you give exact information on healing severe burns?  01:07:52 - Uterine Cancer - Non-Stop Period/Bleeding - Unbearable Cramps - Pain - Weight Loss The Doctor did a biopsy, told me I had 2 masses in my vagina. 01:26:36 - Thyroid Tumor - Balding - Tinnitus - Rashes - High Bilirubin  - High Testosterone Tumor is really big, like the size of a ping-pong ball.

How tumors respond to treatment has to do with both their internal and external environments, research by Valsamo Anagnostou, a cancer researcher at Johns Hopkins, and colleagues has shown. Anagnostou: The way we do this is by looking very deeply … What does the area around a tumor tell us about response to treatment? Elizabeth Tracey reports Read More »

BioOsteosarcoma Webinar Series: Brian Ladle, MD, PhD, Assistant Professor of Oncology and Pediatrics at The Johns Hopkins University School of Medicine, joins us on OsteoBites to discuss deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma.We have learned that more engagement of the immune system and osteosarcoma results in better outcomes - even when patients are given standard chemotherapy. We have found that drugs that activate the STING pathway in osteosarcoma tumors result in greater immune cell invasion into the tumors. This corresponds with improved outcomes when combined with chemotherapy and other immunotherapies. Dr. Ladle will discuss these findings and what steps we are taking to bring this closer to clinical trials for osteosarcoma patients.Dr. Brian Ladle is a pediatric oncologist, sarcoma specialist, and immunotherapy researcher at Johns Hopkins University. His research centers around the goal of generating potent immune responses against pediatric sarcoma tumors - especially osteosarcoma. Ongoing projects encompass preclinical work using osteosarcoma mouse models and osteosarcoma clinical trials in both dogs and humans. He really believes immunotherapy approaches can be effective against osteosarcoma and will become a key piece to "Make It Better" for osteosarcoma patients.

Juno Wollf was born on October 11th of 2022 and was doing well until James noticed a lump under his right armpit. As happens too often, the doctors who looked at Juno did not figure out that this lump was an indication of a Malignant Rhabdoid Tumor, which was finally diagnosed on December 17th of 2022. Just 47 days after Juno's diagnosis on February of 2023, he passed away from this form of Pediatric Cancer, which is diagnosed in 20-25 kids each year. Juno only lived for a total of 114 days. 

“She's so strong.” That's what people say when a woman holds it all together on the outside but what happens when she's quietly suffering inside? In this episode, Heather sits down with entrepreneur and mother Lily Walla, the founder + CEO of Auggie, for a conversation about the stories women often don't tell—the health scares, the quiet fears, the identity crises, and the hidden rage that shapes how we show up as mothers, leaders, and humans. Lily shares how a life-threatening tumor reshaped her sense of self, why she built a parenting community rooted in honesty, and how she's learning to surrender in seasons of uncertainty. In this episode, we talk about:

What happens when a life of service is interrupted by a life-threatening diagnosis? In this powerful episode of SOFcast, hosts Matt Parrish sits down with Major David Carr and his wife Lauren to share their extraordinary journey—one that takes them from the frontlines of special operations to the frontlines of a deeply personal medical battle.After experiencing unexplained symptoms, David—a Green Beret—was diagnosed with a large brain tumor, requiring emergency surgery and resulting in a stroke that left him temporarily paralyzed. Lauren, a longtime government contractor and now caregiver, stepped into a new role—coordinating medical care, navigating military bureaucracy, and advocating for the support they needed to survive the crisis.Together, the Carrs reflect on:The early warning signs and shocking diagnosis that changed their lives overnightThe role of the SOCOM Care Coalition in helping them navigate a complex recoveryThe value of community, advocacy, and leadership during moments of extreme vulnerabilityDavid's path back to active duty, including regaining mobility, setting new physical goals, and returning to serveLauren's voice as a caregiver and advocate, helping others understand the unseen challenges that families faceThis is not just a story about survival—it's about service, resilience, and what it really means to take care of our people.

Sheinbaum lidera reunión climática rumbo a la COP30 desde Palacio Nacional  Médicos del IMSS extirpan tumor de 22.8 kg en QuerétaroVenezuela moviliza 15 mil soldados en su frontera con Colombia Más información en nuestro Podcast

LCC in Greek: Virtual Tumor Board - ALK NSCLC by IASLC

In this episode, we speak with Prof. Johannes Gojo, MD, PhD, one of the world's foremost experts in pediatric neuro-oncology. Dr. Gojo shares groundbreaking research into ETMR and ATRT brain tumors, the promise of liquid biopsies, and how international collaboration through CARE for RARE (established by Solving Kids' Cancer) is transforming outcomes for children with rare brain tumors.We also highlight a newly funded research project, supported by multiple organizations including Gold Ribbon Kids, that aims to deliver precision medicine breakthroughs for some of the most aggressive childhood cancers.Topics CoveredWhy ETMR and ATRT are so difficult to treatThe role of liquid biopsies in monitoring and guiding therapyHow CARE for RARE and global consortia accelerate progressThe impact of family-driven advocacy on scientific discoveryThe hope behind newly funded research initiatives

We would love to pray for you! Please send us your requests here. --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Since 2012, Oregon's Jessamyn Way has endured six brain surgeries for multiple tumors and the removal of her left hippocampus, leaving her with uncontrolled epilepsy. She readily admits that without consuming her own cannabis every four hours, she would not be alive today. Despite these serious health challenges, she has lost half her bodyweight and now competes in triathlons. This powerful episode may change the way you see healing. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

When something bad happens to you, how do you grieve it without getting stuck in suffering? -Halley Elwell Imagine being 11 years old when your face suddenly begins to change. Tumors form on your jaw, and the diagnosis is an incurable condition called Neurofibromatosis. This is the story of singer/songwriter Halley Elwell www.halswellmusic.com. Raised off the grid in Maine by an artist mom, she was told to ignore what was happening to her face and to live her life. She runs free in the woods around her neighborhood, learns to sing old Irish songs, plays piano, and dives into community theatre. In this episode of The Story Behind Her Success, we learn how Halley held onto her light, despite adversity, to become an accomplished singer, songwriter, and advocate for those with facial differences. The secret ingredient? Creativity. Describing her voice, a Maine music critic said: “Imagine Rickie Lee Jones recording with Norah Jones and Natalie Merchant and you'll have an idea of how Elwell's music sounds.” Her latest album and podcast series have the same name: Spontaneous Mutation. Both artistic efforts explore the narratives around facial differences. In science, a spontaneous mutation is a genetic change with no known cause. Halley takes this concept one step further with words, voice, and heart: “When you have an incurable condition, you can't be fixed. But there are different lenses to look through, and that has freed me.” For 25 minutes of inspiration (and the chance to hear Halley's gorgeous voice), just hit that download button. Check out her podcast series here: spontaneousmutation.podbean.com.

BUFFALO, NY – August 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on August 19, 2025, titled “The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo.” In this study, led by first authors Laurence Booth and Michael R. Booth, along with corresponding author Paul Dent from Virginia Commonwealth University, researchers investigated how aramchol, a drug originally developed for liver disease, works with the cancer drug regorafenib in gastrointestinal (GI) tumor cells. They found that the combination is effective, especially in tumor cells with a specific genetic variant. The combined approach offers a potential new strategy for treating liver and colon cancers. Gastrointestinal cancers, such as liver and colon cancer, are serious global health challenges. Regorafenib, already approved for cancer treatment, can have limited impact and frequently causes side effects. Aramchol, a drug developed to treat fatty liver disease, affects how cancer cells process fats and energy. In this study, researchers tested whether combining these two drugs could improve GI cancer treatment, both in cells and mouse models. The results showed that the drug combination killed liver and colorectal cancer cells more effectively than either drug alone. In animal models, mice with human liver tumors had slower tumor growth, without showing signs of weight loss or other toxicity. The researchers also found that aramchol and regorafenib work together to block important survival pathways inside cancer cells. This combination was especially effective in cells with a genetic variant called ATG16L1 T300, which is more common in people of African ancestry. The treatment triggered stress responses in the cancer cells and disrupted key proteins required for survival. It also activated autophagy, a natural recycling process that clears out damaged parts, eventually leading to cancer cell death. “Aramchol interacted with the multi-kinase inhibitors sorafenib, regorafenib or lenvatinib, to kill GI tumor cells, with regorafenib exhibiting the greatest effect.” Aramchol is currently in clinical trials for fatty liver disease and has a well-established safety profile, while regorafenib is already FDA-approved for cancer treatment. Together, their combination could advance fast into clinical testing for patients with GI cancers. However, researchers note that additional studies are needed to support the launch of early-phase clinical trials. Altogether, this study may offer a more effective and less toxic alternative to current treatments for GI cancers. It also highlights the role of genetic variants in shaping treatment response, suggesting that future therapies could be more precisely tailored to each patient's unique genetic profile. DOI - https://doi.org/10.18632/oncotarget.28762 Correspondence to - Paul Dent - paul.dent@vcuhealth.org Video short - https://www.youtube.com/watch?v=5saAqsqxi-Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28762 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, macroautophagy, flux; ER stress, aramchol, regorafenib To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Is divine healing meant to be rare—or a normal part of everyday life? Evangelist and author Chad Gonzales joins Jen Lilley and Billy Hallowell for a powerful conversation on why healing is God's will for everyone, how to live free from sickness, and why most Christians are missing out on the supernatural life Jesus promised.From jaw-dropping miracle stories—blind eyes opening, tumors vanishing, legs growing out—to breaking down common misconceptions about Paul's thorn and the gifts of the Spirit, Chad challenges believers to rethink what's possible when they truly understand their identity in Christ.Topics covered: • Why healing should be a lifestyle, not a rare event • How to shift your focus from sickness to the Healer • The dangers of “panic prayer” • Real-life testimonies that will blow your mind • What the Bible really says about living free from sicknessThis episode will ignite your faith, and stir up a hunger for the supernatural.

In today's Beating Cancer Daily episode, Saranne explores creating a living legacy with excitement and optimism. As someone who has beaten Stage IV cancer for 30 years, Saranne shares her perspective on why it's essential to consciously think about and enjoy crafting a legacy, regardless of the timeline we have. Join her as she discusses fun and creative ways to leave a lasting imprint, from recording books for loved ones to planting living markers of our time. Get ready to be inspired and discover how embracing the concept of legacy can bring joy and depth to our lives as we beat cancer daily together.2025 People's Choice Podcast Awards Finalist Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries across 7 continents and features over 390 original daily episodes hosted by Stage IV survivor  Saranne Rothberg.   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

Thanks for watching the Harland Highway. Tickets to see Harland Williams live stand-up comedy are available now at harlandwilliams.com! -Chubbies and Wayfair sponsor this episode!- Your new wardrobe awaits! Get $10 off @chubbies with the code [HARLANDHIGHWAY] at https://www.chubbiesshorts.com/[HARLANDHIGHWAY] #chubbiespod- -Get organized, refreshed, and back to routine for way less. Head to Wayfair.com right now to shop all things home. Wayfair. Every style. Every home. More Harland Williams: Harland Highway Podcast Video: https://www.youtube.com/c/HarlandHighwayPodcast Harland Highway Podcast Audio: https://podcasts.apple.com/us/podcast/the-harland-highway/id321980603 Instagram: https://www.instagram.com/harlandwilliams Harbling Shirts: https://www.harbling.com Official Website: https://www.harlandwilliams.com Twitter :https://twitter.com/harlandhighway?lang=en More Dr.Drew: Website: https://drdrew.com/ Instagram: https://www.instagram.com/drdrewpinsky/?hl=en #podcast #harlandwilliams Learn more about your ad choices. Visit megaphone.fm/adchoices

Can you manipulate blood flow in the tumor microenvironment to optimize drug delivery? In this episode of the BackTable Podcast, interventional oncologist Dr. Zachary Berman (UC San Diego) joins host Dr. Christopher Beck to discuss real-world applications of pressure-enabled drug delivery in local, regional liver-directed therapies like TACE and Y90.---This podcast is supported by:TriSalus Life Scienceshttp://trinavinfusion.com/---SYNPOSISThe conversation begins with an overview of the tumor microvascular environment, focusing on the abnormal nature of the new vessels that feed tumors. They then discuss the genesis of pressure-enabled drug delivery and the theory behind its efficacy. Dr. Berman explains the TriNav catheter's micro-valve design, its anti-reflux properties, and how these features enhance tumor drug delivery. He walks through his own procedure technique, comparing and contrasting it to standard embolization, and details the utility of pressure-enabled drug delivery in lobar radioembolization and larger tumors. They also explore the benefits of both balloon occlusion and microvalve catheters.Real-world cases—including neuroendocrine tumors, segmental HCC, and more—illustrate the thought process around when to use specialized technologies. The episode wraps up with a discussion of the future implications for this technology in other pathologies, cost considerations, and the potential for enhancing drug delivery with innovative approaches.---TIMESTAMPS00:00 - Introduction01:39 - The Tumor Microenvironment06:59 - Pressure-Enabled Drug Delivery Explained09:37 - Technical Aspects of Pressure-Enabled Catheters21:48 - Case 1: Grade 3 Neuroendocrine Tumor34:06 - Case 2: Hepatocellular Carcinoma with Tumor and Vein36:01 - Case 3: TACE for Segmental HCC in Decompensated Cirrhosis38:58 - Case 4: Large Heterogenous Cholangiocarcinoma40:40 - Case 5: Lobar Neuroendocrine Tumor42:38 - Case 6: Segmental HCC with Central Necrosis47:52 - Best Practices and Technical Considerations57:52 - Future Directions in Pressure-Directed Embolotherapy59:48 - Conclusion and Final Thoughts---RESOURCESJVIR 2024 Jaroch et al.:https://pubmed.ncbi.nlm.nih.gov/38969336/

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Paraneoplastic Effects of Tumors⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

What is in the This Week in Science Podcast? This Week:  Atomic Slits, Vaccines Work, Wifi Fingerprint, Ancient Teeth, Deep Life, Fat for Tumors, Immunity in your head, Cultural Function, Brain Generics, and Much More Science you can trust! Become a Patron! Check out the full unedited episode of our podcast on YouTube or Twitch. […] The post 30 July, 2025 – Episode 1024 – This is the Science You Can Trust appeared first on This Week in Science - The Kickass Science Podcast.

Sir Mixaway. Pulling the dork. It lights up and extends. Tumor pot pie. Wymong? Wy Not Mong? Filling the Hootie Hole. She's got some juicy doubles. Great swelling moments. Pisstory. X-Men or Disney Beast? Yes. Where In the World is Carmen Sandiego, You Know I Wanna Date Her. Sharkagator. Many Tabs Died to Bring You This Information. Red Button, Green Button, With Tom. Private Movielicious with Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.